A recent study successfully developed a peptide targeting the interaction between programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1), which activates the immune response and suppresses tumor progression [28]. Here, PDCD1 is linked to neoplasm.